Assessment of ECMO in acute myocardial infarction with Non-reversible Cardiogenic shock to Halt Organ failure and Reduce mortality
ANCHOR is a multicenter, randomized, controlled trial. It’s primary objective is to determine if early VA-ECMO in conjunction with optimal medical treatment would improve clinical outcomes 30 days following randomization as compared with optimal medical treatment alone in patients with acute myocardial infarction complicated by cardiogenic shock.
ECMO PT is a multicentre, randomised, trial of whether early individualised physical training (commenced within first 48 hours of ECMO) is feasible and improves functional recovery (the highest level of activity and duration) compared to standard care in ECMO patients.
ECCO2R Position paper
This position paper will represent the expert opinion of an international group of physicians and allied health-care professionals who have expertise relevant to the use of extracorporeal CO2 removal (ECCO2R) in clinical trials and practice. It will provide clinicians, ECCO2R providers, policy makers and clinical researchers with a concise summary of the technology and its use in research and clinical practice. This information informs a summary of recommendations for the use of ECCO2R and areas where there is a requirement for further study.
Venovenous ECMO Position Paper
A position paper on the provision of venovenous ECMO is planned.